RU2006133903A - Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани - Google Patents
Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани Download PDFInfo
- Publication number
- RU2006133903A RU2006133903A RU2006133903/14A RU2006133903A RU2006133903A RU 2006133903 A RU2006133903 A RU 2006133903A RU 2006133903/14 A RU2006133903/14 A RU 2006133903/14A RU 2006133903 A RU2006133903 A RU 2006133903A RU 2006133903 A RU2006133903 A RU 2006133903A
- Authority
- RU
- Russia
- Prior art keywords
- measured
- marker
- bone
- bone resorption
- serum
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 15
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract 4
- 210000000988 bone and bone Anatomy 0.000 title claims abstract 3
- 230000002265 prevention Effects 0.000 title claims 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract 22
- 208000006386 Bone Resorption Diseases 0.000 claims abstract 19
- 230000024279 bone resorption Effects 0.000 claims abstract 19
- 239000003550 marker Substances 0.000 claims abstract 16
- 210000002966 serum Anatomy 0.000 claims abstract 12
- 229960003624 creatine Drugs 0.000 claims abstract 11
- 239000006046 creatine Substances 0.000 claims abstract 11
- 102000012422 Collagen Type I Human genes 0.000 claims abstract 9
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 229940096422 collagen type i Drugs 0.000 claims abstract 8
- 108010022452 Collagen Type I Proteins 0.000 claims abstract 7
- 230000011164 ossification Effects 0.000 claims abstract 7
- 230000004097 bone metabolism Effects 0.000 claims abstract 6
- 210000002700 urine Anatomy 0.000 claims abstract 4
- 150000002148 esters Chemical class 0.000 claims abstract 3
- 239000002207 metabolite Substances 0.000 claims abstract 3
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims abstract 3
- 229960003969 ospemifene Drugs 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims 2
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims 2
- 108010050808 Procollagen Proteins 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/783,092 | 2004-02-23 | ||
| US10/783,092 US20050187302A1 (en) | 2004-02-23 | 2004-02-23 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
| PCT/FI2005/000034 WO2005079776A1 (en) | 2004-02-23 | 2005-01-19 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006133903A true RU2006133903A (ru) | 2008-03-27 |
Family
ID=34861145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006133903/14A RU2006133903A (ru) | 2004-02-23 | 2005-01-19 | Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050187302A1 (https=) |
| EP (1) | EP1718287A1 (https=) |
| JP (1) | JP2007523209A (https=) |
| CN (1) | CN1972680A (https=) |
| AU (1) | AU2005215173A1 (https=) |
| BR (1) | BRPI0507912A (https=) |
| CA (1) | CA2557116A1 (https=) |
| MX (1) | MXPA06009549A (https=) |
| NO (1) | NO20064007L (https=) |
| RU (1) | RU2006133903A (https=) |
| WO (1) | WO2005079776A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| EP1986655A4 (en) * | 2006-02-06 | 2009-12-23 | Tethys Bioscience Inc | MARKERS ASSOCIATED WITH OSTEOPOROSIS AND METHODS OF USE |
| CA2677861C (en) * | 2007-02-14 | 2015-05-19 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
| US7504530B2 (en) * | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
| JP5010034B2 (ja) * | 2007-12-28 | 2012-08-29 | エフ．ホフマン−ラ ロシュ アーゲー | 生理学的状態の評価 |
| CN102690347B (zh) * | 2012-05-18 | 2014-06-25 | 北京北方生物技术研究所 | 分离i型前胶原氨基末端肽的方法 |
| WO2014060639A1 (en) | 2012-10-19 | 2014-04-24 | Fermion Oy | A process for the preparation of ospemifene |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
-
2004
- 2004-02-23 US US10/783,092 patent/US20050187302A1/en not_active Abandoned
-
2005
- 2005-01-19 BR BRPI0507912-8A patent/BRPI0507912A/pt not_active IP Right Cessation
- 2005-01-19 AU AU2005215173A patent/AU2005215173A1/en not_active Abandoned
- 2005-01-19 CA CA002557116A patent/CA2557116A1/en not_active Abandoned
- 2005-01-19 JP JP2007500232A patent/JP2007523209A/ja not_active Abandoned
- 2005-01-19 MX MXPA06009549A patent/MXPA06009549A/es unknown
- 2005-01-19 CN CNA2005800049712A patent/CN1972680A/zh active Pending
- 2005-01-19 RU RU2006133903/14A patent/RU2006133903A/ru not_active Application Discontinuation
- 2005-01-19 WO PCT/FI2005/000034 patent/WO2005079776A1/en not_active Ceased
- 2005-01-19 EP EP05708122A patent/EP1718287A1/en not_active Ceased
-
2006
- 2006-09-06 NO NO20064007A patent/NO20064007L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007523209A (ja) | 2007-08-16 |
| CN1972680A (zh) | 2007-05-30 |
| EP1718287A1 (en) | 2006-11-08 |
| NO20064007L (no) | 2006-09-21 |
| WO2005079776A1 (en) | 2005-09-01 |
| US20050187302A1 (en) | 2005-08-25 |
| AU2005215173A8 (en) | 2009-09-24 |
| MXPA06009549A (es) | 2007-04-10 |
| AU2005215173A1 (en) | 2005-09-01 |
| BRPI0507912A (pt) | 2007-07-10 |
| CA2557116A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| DE69936848D1 (de) | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie | |
| DE60044213D1 (de) | Stabilisierte flüssige pharmazeutische Zusammensetzung enthaltend TFPI | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| EA200400154A1 (ru) | Новые лекарственные формы замещенного бензимидазола и способ их применения | |
| DE60112301D1 (de) | Verwendung von (deaminohydroxy)toremifene zur behandlung von vaginalen trockenheit oder sexuellen störung während und nach der menopause | |
| ATE447858T1 (de) | Pharmazeutische zusammensetzung für muskelanabolismus | |
| BR0314619A (pt) | Análogos de ghrh | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| RU2006133903A (ru) | Способ лечения или профилактики остеопороза у индивидуумов с высоким обменом костной ткани | |
| HUP0400120A2 (hu) | Mellékpajzsmirigy hormon és kalcitonin orális adagolására szolgáló gyógyászati készítmény | |
| Kukreja et al. | Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer | |
| Okada et al. | Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice | |
| RU2005105691A (ru) | Пероральное введение кальцитонина | |
| JP2007537297A (ja) | 骨質量を調節するための骨を標的化する部分と結合体化したβアドレナリン薬物 | |
| SE8903529D0 (sv) | Medical use | |
| Mikosch et al. | High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy | |
| JP2007523209A5 (https=) | ||
| ATE344025T1 (de) | Behandlung oder prävention von urogenitaler atrophie und deren symptomen bei frauen | |
| RU2009127858A (ru) | Фармацевтическая композиция, включающая алискирен и авосентан | |
| WO2000019823A9 (en) | Methods of screening for apoptosis-controlling agents for bone anabolic therapies and uses thereof | |
| MXPA05011862A (es) | Uso de derivados de acido fenoxiacetico para tratamiento de vejiga hiperactiva. | |
| Sakallioğlu et al. | Effects of Excessive Fluoride intake on Bone Turnover in Mandible: An Immunohistochemical Study in Rabbits | |
| Matreja et al. | Newer Approaches in the Treatment of Osteoporosis | |
| Bolzonella et al. | Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090302 |